Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care ##### Up next ###### [Monport Laser Strengthens Black Friday Lineup with Professional-Grade Laser Engraving Solutions](https://thailandbusinessnews.net/press-release/monport-laser-strengthens-black-friday-lineup-with-professional-grade-laser-engraving-solutions/) Published on 19 November 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) JERUSALEM, Nov. 19, 2025 /PRNewswire/ — Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract is valued at up to $186 million, including all option periods. This pivotal collaboration, which represents Rafa’s second major contract with BARDA, addresses an urgent global need: a rapidly deployable, easy-to-administer treatment for hemorrhage in the critical prehospital setting. Addressing the Critical Window to Save Lives Uncontrolled bleeding is the leading cause of preventable death following trauma, whether caused by accidents, mass-casualty events or in the battlefield. Caregivers need a tool which can be easily administered to a large number of casualties in a short period of time. TXA is an antifibrinolytic agent commonly used off label around the world to treat trauma bleeding in the pre-hospital and hospital space. Landmark clinical studies performed in tens of thousands of individuals have demonstrated that TXA can significantly reduce mortality rates if administered quickly enough following trauma hemorrhagic injury. "The clock starts ticking the moment a patient sustains a hemorrhagic injury, and the few minutes before reaching a hospital are the most critical ones," said Roy Shay, Vice President of Biodefense at Rafa Laboratories. "Currently, TXA is typically administered intravenously (IV), which is challenging, time-consuming and requires training. The need for trained individuals even greater in high-stress, or mass-casualty situations. Developing a new intramuscular TXA injection is a potential game-changer as it simplifies the administration process, especially if administered with an autoinjector. As planned under the potential scope of this project, Rafa shall also develop a TXA autoinjector which will enable professional as well as nonprofessional care givers to deliver this essential treatment instantly—dramatically increasing survival chances worldwide." "The IM route offers a fast, reliable, and user-friendly alternative for the existing IV administration, which can be extremely difficult in patients experiencing severe shock". BARDA and Rafa are Collaborating on a Comprehensive Development Approach Rafa Laboratoriesis adopting a robust and integrated product development approach, which is planned to include formulation development, manufacturing scale-up, pre/clinical trials and a streamlined regulatory pathway designed to secure U.S. Food and Drug Administration (FDA) approval. "Over the past four decades, Rafa has built a reputation for developing highly dependable medical countermeasures targeting acute, life-threatening conditions, mainly CBRN and pain management." said Iddo Leshem, Chief Executive Officer of Rafa Laboratories. "The IM TXA development contract marks a strategic expansion of Rafa’s presence in acute trauma care. We are deeply committed to partnering with BARDA to accelerate the delivery of this urgently needed, life-saving solution to hundreds of thousands of patients across the globe". About Rafa Laboratories Founded in 1937 and headquartered in Jerusalem, Israel, Rafa Laboratories is a global leader in biodefense and emergency medical solutions. For more than 40 years, Rafa has supplied medical countermeasure autoinjectors to the U.S. federal government, NATO allies, military forces, and civilian stockpiles worldwide, including its Midazolam 10 mg autoinjector (US-FDA approved under NDA #216359 since 2022) and Atropine autoinjector (US-FDA approved under NDA #212319 for 2 mg since 2018 and EUA # for 0.5 & 1 mg since 2017). The company’s expertise spans the entire value chain — from a robust R&D pipeline addressing emerging threats, to cGMP-compliant manufacturing and successful regulatory approvals from the U.S. FDA and European health authorities. Rafa’s controlling shareholder, FIMI Opportunity Funds, is Israel’s leading private equity fund. With over 25 years of experience, FIMI manages assets of $7 billion and has completed nearly 100 investments globally. This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50125C00018. Media Contact:Roy ShayVP, BiodefenseRafa Laboratories [Source link ](https://www.prnasia.com/story/archive/4826285_EN26285_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/indian-families-chase-the-chill-with-30-rise-in-cold-weather-travel-interest-this-festive-holiday-season/) ![Indian Families Chase the Chill with 30% Rise in Cold-Weather Travel Interest This Festive Holiday Season](https://i0.wp.com/mma.prnasia.com/media2/2567836/Agoda.jpg?resize=260%2C140&ssl=1 "Indian Families Chase the Chill with 30% Rise in Cold-Weather Travel Interest This Festive Holiday Season") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Indian Families Chase the Chill with 30% Rise in Cold-Weather Travel Interest This Festive Holiday Season South Korea, China, and Austria lead growth in family travel interest for… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - December 1, 2025 [](https://thailandbusinessnews.net/press-release/ericsson-and-vodafone-announce-major-five-year-programmable-networks-partnership/) ## Ericsson and Vodafone announce major five-year programmable networks partnership Ericsson will be Vodafone’s sole radio access network (RAN) vendor nationwide across… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - October 14, 2025 [](https://thailandbusinessnews.net/press-release/corvia-medical-closes-55-million-funding-round-to-complete-confirmatory-trial-and-pursue-fda-approval-of-corvia-atrial-shunt/) ## Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, Mass.,… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - June 17, 2025 ##### Most Read - [![Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/priority-pass-to-accelerate-travel-innovation-backed-by-the-collinson-groups-500-million-growth-programme-2/ "Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme") [Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme](https://thailandbusinessnews.net/press-release/priority-pass-to-accelerate-travel-innovation-backed-by-the-collinson-groups-500-million-growth-programme-2/ "Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme") - [![Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material](https://i0.wp.com/r2.thailandbusinessnews.net/2025/04/MODERN_MEADOW_LOGO_BLACK_PNG_Logo.jpg?fit=597%2C138&ssl=1&resize=40%2C40)](https://thailandbusinessnews.net/press-release/modern-meadow-and-bellroy-partner-on-carry-products-made-of-next-generation-material/ "Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material") [Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material](https://thailandbusinessnews.net/press-release/modern-meadow-and-bellroy-partner-on-carry-products-made-of-next-generation-material/ "Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material") - [![IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/img-completes-acquisition-of-world-nomads-expanding-global-travel-insurance-distribution/ "IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution") [IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution](https://thailandbusinessnews.net/press-release/img-completes-acquisition-of-world-nomads-expanding-global-travel-insurance-distribution/ "IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution") - [![DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/dorco-wins-2026-red-dot-award-for-renewed-corporate-identity/ "DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity") [DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity](https://thailandbusinessnews.net/press-release/dorco-wins-2026-red-dot-award-for-renewed-corporate-identity/ "DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity") - [![Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/tamarind-health-launches-rare-cancer-centre-to-make-specialist-expertise-easier-to-access/ "Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access") [Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access](https://thailandbusinessnews.net/press-release/tamarind-health-launches-rare-cancer-centre-to-make-specialist-expertise-easier-to-access/ "Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access") - [![MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/memomind-one-rolls-out-new-features-and-prepares-for-a-new-stage-of-developer-access/ "MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access") [MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access](https://thailandbusinessnews.net/press-release/memomind-one-rolls-out-new-features-and-prepares-for-a-new-stage-of-developer-access/ "MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/discovering-indonesia-through-experiences-beyond-the-ordinary/) ![Discovering Indonesia Through Experiences Beyond the Ordinary](https://i0.wp.com/mmx.prnasia.com/media/MS2001398/20260930223712EDT_image_1.jpg?resize=260%2C140&ssl=1 "Discovering Indonesia Through Experiences Beyond the Ordinary") ## Discovering Indonesia Through Experiences Beyond the Ordinary SEOUL, South Korea, Oct. 2, 2026 /PRNewswire/ —… [](https://thailandbusinessnews.net/press-release/vestas-powers-up-vietnams-clean-energy-ambitions-with-two-new-projects-under-pdp8-totaling-16-wind-turbines/) ![Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines](https://i0.wp.com/mmx.prnasia.com/media/MS2001368/20261002002233EDT_image_2.jpg?resize=260%2C140&ssl=1 "Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines") ## Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines HANOI, Vietnam, Oct. 2, 2026 /PRNewswire/ — Vestas has been awarded contracts… [](https://thailandbusinessnews.net/press-release/iqiyi-aigc-series-the-ferry-man-exceeds-rmb-8-million-in-revenue-sharing-as-third-instalment-debuts-on-october-1/) ![iQIYI AIGC Series "The Ferry Man" Exceeds RMB 8 Million in Revenue-Sharing as Third Instalment Debuts on October 1](https://i0.wp.com/mmx.prnasia.com/media/MS2001352/20261001223355EDT_image_1.jpg?resize=260%2C140&ssl=1 "iQIYI AIGC Series "The Ferry Man" Exceeds RMB 8 Million in Revenue-Sharing as Third Instalment Debuts on October 1") ## iQIYI AIGC Series "The Ferry Man" Exceeds RMB 8 Million in Revenue-Sharing as Third Instalment Debuts on October 1 BEIJING, Oct. 2, 2026 /PRNewswire/ — iQIYI, China’s leading online… [](https://thailandbusinessnews.net/press-release/the-anime-kagurabachi-casts-yuichi-nakamura-as-soshiro-azami-cast-comments-character-visual-trailer-revealed/) ![The Anime "KAGURABACHI" Casts Yuichi Nakamura as Soshiro Azami; Cast Comments, Character Visual & Trailer Revealed!](https://i0.wp.com/mmx.prnasia.com/media/MS2001335/20261001214223EDT_image_1.jpg?resize=260%2C140&ssl=1 "The Anime "KAGURABACHI" Casts Yuichi Nakamura as Soshiro Azami; Cast Comments, Character Visual & Trailer Revealed!") ## The Anime "KAGURABACHI" Casts Yuichi Nakamura as Soshiro Azami; Cast Comments, Character Visual & Trailer Revealed! TOKYO, Oct. 2, 2026 /PRNewswire/ — The anime Kagurabachi, based on a…